Q2 2026 Zai Lab Ltd Earnings Call Transcript

Aug 6, 2026 / 12:00 PM GMT

Release Date Price: $20.88 (+13.66%)

Transcript 10-Q8-K

Key Points

Positve

Zai Lab Ltd (ZLAB) has reached an inflection point, transitioning from a regional business into a global biopharmaceutical company with its first U.S. regulatory submission expected next year.
The company's lead asset, ZL-1310 (DLL3 ADC), is advancing rapidly, with three registrational programs expected by year-end in small cell lung cancer and neuroendocrine carcinoma, and a potential U.S. approval anticipated in 2028.
Net product revenue grew 11% sequentially in Q2 2026 to $105.8 million, and the commercial business remained profitable, with strong demand for key brands like VYVGART and a promising launch for COBENFY.
The pipeline includes ZL-1503, a potential first-in-class bispecific for atopic dermatitis, which is advancing quickly with first-in-human data expected later this year and a differentiated profile targeting both IL-13 and IL-31 pathways.
The company ended the quarter with a strong cash position of $717.5 million, providing financial flexibility to invest in high-value global programs while maintaining disciplined operating expenses.
Zai Lab Ltd (ZLAB) is executing on multiple global collaborations, including with Amgen and Boehringer Ingelheim, to explore combination therapies that could expand the utility of its DLL3 ADC.

Negative

The company has deferred its previous profitability goal, indicating that operating expenses will remain broadly stable as it prioritizes investment in global pipeline programs over near-term profitability.
Reported revenue in the second half of 2026 may not fully reflect underlying demand due to timing of NRDL-related commercial dynamics, particularly for the VYVGART franchise as it transitions from IV to SubQ.
The competitive landscape for atopic dermatitis treatments is intensifying, with new entrants and increased investor interest in IL-13/IL-31 targeting assets, which could pressure ZL-1503's market potential.
The company's commercial business in China faces challenges, including supply constraints for certain products and the need to stabilize sales before returning to meaningful growth in 2027.
The DLL3 ADC combination studies with T-cell engagers are still early-stage, and data readouts are not expected until the second half of next year, leaving uncertainty around the ultimate efficacy and safety of these regimens.
The company's transition to a global biopharmaceutical model involves significant execution risks, including the need to successfully complete global registration trials and navigate regulatory pathways in the U.S.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

9688.HK - Zai Lab Ltd
Q2 2026 Zai Lab Ltd Earnings Call
Aug 06, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello, ladies and gentlemen.

Thank you for standing by and welcome to Xilabs Second Quartile 2026 Financial Results Conference Call.

At this time, all participants are in listen-only mode. Later, we'll conduct a question-and-answer session, and instructions will follow at a time.

As a reminder, today's call is being recorded.

It is now my pleasure to turn the floor over to Christine Cho, Senior Vice President of the Investor Relations. Please go ahead, ma'am.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Hello and welcome, everyone.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.